Search for content, post, videos

Oncopeptides appoints new Chief Financial Officer

The company has appointed Holger Lembrer as Chief Financial Officer, CFO.

Prior to joining Oncopeptides Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika Muskantor who has been interim CFO since November 1, 2021.

“I am very pleased that Holger Lembrer has decided to join Oncopeptides, and really look forward to working together with him,” says Monica Shaw, CEO of Oncopeptides. “His combined expertise from leading financial roles, in a highly recognized, publicly traded, international Company, will be a great asset for Oncopeptides and its Leadership Team.”

Photo of Holger Lembrer: Oncopeptides